nature portfolio

Corresponding author(s):	Alaa Abd-Alrazaq
Last updated by author(s):	Apr 9, 2023

Reporting Summary

Statistics

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
\times		The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
\boxtimes		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
\boxtimes		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
\boxtimes		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
\boxtimes		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\times		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So	ftw	vare and code
Poli	cy in	formation about <u>availability of computer code</u>

Data analysis N/A

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Data collection

Policy information about <u>availability of data</u>

N/A

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data that support the findings of this study are available from the corresponding author upon reasonable request

Field-specific reporting					
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.					
Life sciences	Behavioural & social s	ciences Ecological, evolutionary & environmental sciences			
For a reference copy of	the document with all sections, see <u>nature.cor</u>	n/documents/nr-reporting-summary-flat.pdf			
Life scier	nces study desigi	า			
All studies must disclose on these points even when the disclosure is negative.					
Sample size	N/A				
Data exclusions	N/A				
Replication N/A					
Randomization N/A					
Blinding N/A					
Donortin	a for en ocific ma	torials systems and mothods			
Reporting for specific materials, systems and methods					
	71	sterials, experimental systems and methods used in many studies. Here, indicate whether each material, ot sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & experimental systems Methods					
· · · · · · · · · · · · · · · · · · ·		/a Involved in the study			
Antibodies		ChIP-seq			
Eukaryotic cell lines		Flow cytometry			
Palaeontology and archaeology		MRI-based neuroimaging			
Animals and other organisms					
Human res	Human research participants				

Clinical data
Dual use research of concern